Source comparison
CJC-1295 no DAC Alternatives 2026: Peptide Comparison
Before designing a protocol, researchers must understand how these alternatives differ across the variables that matter most in experimental design. CJC-1295 no DAC GHRH receptor agonist Moderate (baseline-dependent) 30 min–2 hr None Minimal Clean GHRH pathway
This comparison does not assign a generated winner or score.
- Before designing a protocol, researchers must understand how these alternatives differ across the variables that matter most in experimental design.
- CJC-1295 no DAC
- GHRH receptor agonist
- Moderate (baseline-dependent)
- 30 min–2 hr
- None
- Minimal
- Clean GHRH pathway studies, sustained protocols
- Gold standard for isolated GHRH signaling without off-target effects
- Ipamorelin
- Ghrelin receptor agonist (highly selective)
- Moderate-Strong
- ~2 hr
- Minimal (none clinically significant)
- Low
- GH-only studies, chronic protocols, selectivity required
- Cleanest ghrelin agonist. GH pulse without cortisol/prolactin noise
- Hexarelin
- Ghrelin receptor agonist (non-selective)
- Very Strong
- ~70 min
- Moderate (cortisol, prolactin)
- High (7–14 days)
- Acute maximal GH stimulation, cardioprotective research
- Largest GH pulse available, but unusable for chronic dosing
- GHRP-2
- Ghrelin receptor agonist (moderate selectivity)
- Strong
- ~20 min
- Mild (cortisol, prolactin)
- Moderate
- Metabolic studies, appetite research, sustained GH elevation
- Best middle-ground option. Strong pulse, tolerable for repeated dosing
- GHRP-6
- Strong (cortisol, prolactin, hunger)
- Appetite/ghrelin pathway studies
- High hunger signaling limits use in GH-focused studies
- Key variables to prioritize when selecting among CJC-1295 no DAC alternatives: if the hypothesis requires isolating GH effects without appetite or stress hormone confounds, Ipamorelin is the only viable choice. If the protocol involves acute single-dose maximal stimulation (e.g., GH reserve testing), Hexarelin delivers the largest measurable pulse. If the study timeline exceeds two weeks with repeated dosing, both Ipamorelin and GHRP-2 maintain response where Hexarelin fails. For metabolic research where ghrelin pathway activation is part of the experimental context, GHRP-2 provides both GH elevation and hunger signaling in one compound.